16 July 2012 | Position statement
As one of the most important generic drug producers, India became the main “pharmacy” of developping countries. Generics represent 80% of treatments purchased by international donors in 115 low and middle income countries. Since 2007, European Union and India negociate bilateral free trade agreements which reinforce intellectual property rights and undermine access to cheap health products, such as vaccines or essential medicines.
Solthis and several associations mobilized in 2011 demanded to the European Union and India to remove measures strengthening intellectual property rights.
On 4th july 2012, the European Parlamentarians vote against the Anti-Counterfeiting Trade Agreement (ACTA) with a very large majority : 478 against, 165 abstentions and only 39 in favour.